Richard Marshall
Fortune : 22 417 $ au 31/05/2026
Fortune : 22 417 $ au 31/05/2026
Richard Marshall is Chief Executive Officer at Juvenescence Ltd. and Juvenescence Therapeutics Ltd. since 2023.
Since 2024, Dr. Marshall is an Independent Director at Serina Therapeutics, Inc. From 2019 to 2023, Dr. Marshall was SVP, Global Head-Respiratory & Immunology at AstraZeneca PLC.
From 2002 to 2018, Dr. Marshall was Vice President-Fibrosis Research & Development at GSK Plc.
Dr. Marshall completed undergraduate and doctorate degrees at University College London.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,08 % | 17/06/2026 | 12 183 ( 0,08 % ) | 22 417 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Directeur Général | 16/01/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2023 |
| GSK PLC | Corporate Officer/Principal | 01/01/2018 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national